Reach Us +1 218 451 2974
Aripiprazole Does Not Attenuate The Benefits Of Environmental Enrichment After Experimental Brain Trauma | 64050
ISSN: 2155-9562

Journal of Neurology & Neurophysiology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Aripiprazole does not attenuate the benefits of environmental enrichment after experimental brain trauma

11th World Congress on Neurology and Therapeutics

Anthony E Kline

University of Pittsburgh, USA

ScientificTracks Abstracts: J Neurol Neurophysiol

DOI: 10.4172/2155-9562.C1.046

Introduction: The typical antipsychotic drug (APD) haloperidol (HAL), a D2 receptor antagonist, has been shown to impede functional outcome after experimental traumatic brain injury (TBI). Furthermore, the deleterious effects persist for up to 3 months after drug withdrawal. Moreover, a recent study showed that HAL reduced the effectiveness of environmental enrichment (EE), a preclinical model of neurorehabilitation. Because agitation is common after TBI, patients are provided APDs so that they can be safely managed. However, many patients in rehabilitation will only experience agitation occasionally and thus will receive APDs intermittently. Hypotheses: Aripiprazole (ARIP), a partial D2 receptor agonist, will not impair recovery or reduce the effectiveness of EE regardless of whether administered once every day (i.e., chronic agitation) or once every other day (occasional agitation). Methods: Anesthetized adult male rats received a cortical impact of moderate severity or sham injury and were then randomly assigned to EE or standard (STD) housing. Treatments with ARIP (0.1 mg/kg; i.p.) or vehicle (VEH; 1.0 mL/kg; i.p.) began 24 hr after injury and continued once daily for 19 days, or once every other day for the same period. Motor and cognitive outcome were assessed on post-operative days 1-5 and 14-19, respectively. Results: Motor and cognitive function was significantly improved in the TBI+EE+VEH vs. TBI+STD+VEH group (p<0.05). Moreover, the TBI+EE+ARIP groups, regardless of dosing regimen, performed significantly better on all endpoints relative to the TBI+STD+VEH controls (p<0.05), but did not differ from one another or from TBI+EE+VEH (p>0.05). Conclusions: ARIP, unlike HAL, did not impair recovery or reduce the efficacy of EE, which supports the hypothesis. Significance: ARIP is beneficial on its own and does not negate the benefits of rehabilitation (i.e., EE) and thus may be used to control TBI-induced agitation and aggression without compromising recovery.

Anthony E Kline, PhD, is a Professor in the Departments of Physical Medicine and Rehabilitation, Critical Care Medicine, and the Safar Center for Resuscitation Research at the University of Pittsburgh. His research includes neurobehavioral recovery and learning after Traumatic Brain Injury (TBI). Therapeutic strategies that include pharmacotherapy and environmental enrichment are utilized alone or in combination in an attempt to restore function and/or attenuate TBI-induced deficits. Another interest is the evaluation of pharmacological agents that may alter TBI and to elucidate potential mechanisms for the observed effects.

Email: [email protected]

Relevant Topics